Global Pancreatic and Biliary Stent Market Size By Type (Plastic Pancreatic And Biliary Stent, Metal Pancreatic And Biliary Stent), By Application (Hospitals, Specialty Clinics), By Region, And Segmen...

The Global Pancreatic and Biliary Stent Market was valued at USD 412 million in 2023 and is expected to reach USD 752 million by 2031, growing at a CAGR of 7.7% during the forecast period (2023–2031). The market is primarily driven by the rising incidence of pancreatic and biliary diseases, advancements in minimally invasive surgical techniques, and the increasing preference for endoscopic interventions over traditional open surgeries. These stents are vital for restoring bile or pancreatic duct patency in cases of obstruction due to malignancies, gallstones, or post-surgical complications.

Drivers:

1. Increasing Incidence of Pancreatic and Biliary Disorders:

The global burden of conditions such as pancreatic cancer, cholangiocarcinoma, and chronic pancreatitis is rising, leading to a higher demand for stent placements to alleviate ductal obstructions and improve patient outcomes.

2. Technological Advancements in Stent Design:

The development of bioabsorbable, drug-eluting, and covered metallic stents has significantly improved the effectiveness and safety of pancreatic and biliary stenting procedures, reducing complications like migration and occlusion.

3. Rising Preference for Minimally Invasive Endoscopic Procedures:

Endoscopic Retrograde Cholangiopancreatography (ERCP) with stent placement is gaining traction due to reduced hospital stays, fewer complications, and better patient compliance, fueling market growth.

Restraints:

1. High Costs of Advanced Stents and Procedures:

The cost of drug-eluting and fully covered metallic stents, combined with procedure-related expenses, can be prohibitive, especially in low-income regions, limiting market penetration.

2. Risks of Stent-Related Complications:

Despite technological improvements, complications such as stent migration, clogging, and infection remain concerns, which may affect long-term adoption among certain patient populations.

Opportunity:

1. Expansion into Emerging Healthcare Markets:

Countries in Asia-Pacific, Latin America, and the Middle East are expanding access to advanced diagnostic and therapeutic tools, creating new opportunities for pancreatic and biliary stent manufacturers.

2. Integration of Imaging and Stent Navigation Technologies:

Real-time imaging and AI-assisted navigation are enhancing stent placement accuracy and safety, offering new frontiers for innovation in stent deployment systems.

Market by System Type Insights:

The market is segmented into plastic stents, self-expanding metal stents (SEMS), and drug-eluting stents. In 2023, self-expanding metal stents held the largest market share due to their superior patency rates and lower re-intervention needs. These are especially preferred in malignant strictures. However, drug-eluting stents are projected to grow at the fastest rate owing to their potential to reduce tumor ingrowth and prolong stent patency.

Market by End-use Insights:

Hospitals dominated the end-use segment in 2023, accounting for over 60% of the market share, due to the availability of advanced endoscopy suites and specialized gastroenterologists. Ambulatory surgical centers (ASCs) are expected to witness robust growth during the forecast period, driven by the increasing shift towards outpatient care and the cost-effectiveness of minimally invasive procedures.

Market by Regional Insights:

North America led the global pancreatic and biliary stent market in 2023, backed by a high prevalence of pancreatic cancer, strong reimbursement frameworks, and the presence of leading medical device manufacturers. Asia-Pacific is expected to register the fastest growth, fueled by healthcare infrastructure improvements, increasing healthcare expenditure, and rising awareness about early diagnosis and treatment of pancreatic and biliary diseases.

Competitive Scenario:

Key players in the global pancreatic and biliary stent market include Boston Scientific Corporation, Cook Medical, Medtronic plc, CONMED Corporation, Olympus Corporation, Taewoong Medical Co., Ltd., Becton, Dickinson and Company, and Biliary Technology, Inc. These companies are actively focusing on R&D, product launches, strategic collaborations, and regulatory approvals to enhance their market position.

Recent Developments:

In 2023, Boston Scientific launched a next-generation drug-eluting biliary stent designed to reduce tissue ingrowth and improve long-term patency.

Cook Medical introduced a novel fully covered SEMS with repositioning capabilities to reduce migration risks.

Olympus Corporation expanded its ERCP product portfolio in 2024 with AI-enhanced navigation for complex biliary access.

Scope of Work – Global Pancreatic and Biliary Stent Market

Report Metric Details

Market Size (2023) USD 412 million

Projected Market Size (2031) USD 752 million

CAGR (2023–2031) 7.7%

Market Segments System Type (Plastic Stents, SEMS, Drug-Eluting), End-use (Hospitals, ASCs)

Growth Drivers Rising disease incidence, technological innovation, shift to minimally invasive procedures

Opportunities Emerging markets, AI-guided navigation, advanced stent technology

Key Market Developments:

Boston Scientific (2023): Rolled out its first bioabsorbable biliary stent in pilot markets.

Cook Medical (2024): Received CE Mark approval for its new covered SEMS with anti-reflux valve technology.

Taewoong Medical (2023): Partnered with a European hospital network to distribute advanced SEMS for complex pancreatic strictures.

FAQs:

1